XML 38 R26.htm IDEA: XBRL DOCUMENT v3.25.3

Collaborations, contracts and licensing agreements (Tables)

9 Months Ended

Sep. 30, 2025

Revenue from Contract with Customer [Abstract]

Summary of collaborations

Revenues are summarized in the following table:

			Three Months Ended September 30,												Nine Months Ended September 30,
			2025						2024						2025						2024
			(in thousands)												(in thousands)
Revenue from collaborations and licenses
Acuitas Therapeutics, Inc.			$	280					$	644					$	1,375					$	1,981
Qilu Pharmaceutical Co., Ltd.			—						123						10,434						880
Non-cash royalty revenue
Alnylam Pharmaceuticals, Inc.			249						572						1,223						1,736
Total revenue			$	529					$	1,339					$	13,032					$	4,597

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration